CARIBOU BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.5 USD | -6.17% |
|
-5.15% | -38.92% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 908.3 | 383.1 | 506.7 | 316.1 | - | - |
| Enterprise Value (EV) 1 | 908.3 | 383.1 | 506.7 | 316.1 | 316.1 | 316.1 |
| P/E ratio | -7.15 x | -3.83 x | -4.15 x | -1.87 x | -1.62 x | -1.69 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 94.6 x | 27.7 x | 14.7 x | 36.2 x | 29.7 x | 4.45 x |
| EV / Revenue | 94.6 x | 27.7 x | 14.7 x | 36.2 x | 29.7 x | 4.45 x |
| EV / EBITDA | -13.8 x | -3.66 x | -4.5 x | -1.81 x | -1.55 x | -4.88 x |
| EV / FCF | - | - | -4.83 x | -2.08 x | -1.7 x | -1.54 x |
| FCF Yield | - | - | -20.7% | -48% | -58.9% | -65% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 60,192 | 61,002 | 88,431 | 90,318 | - | - |
| Reference price 2 | 15.09 | 6.280 | 5.730 | 3.500 | 3.500 | 3.500 |
| Announcement Date | 21/03/22 | 09/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 9.598 | 13.85 | 34.48 | 8.733 | 10.64 | 71.03 |
| EBITDA 1 | - | -66 | -104.8 | -112.5 | -174.9 | -204.4 | -64.75 |
| EBIT 1 | - | -66.98 | -106.4 | -116.1 | -197.4 | -243.1 | -232 |
| Operating Margin | - | -697.84% | -768.17% | -336.63% | -2,260.88% | -2,285.88% | -326.64% |
| Earnings before Tax (EBT) 1 | - | -66.6 | -99.35 | -101.9 | -184.9 | -234.4 | -229 |
| Net income 1 | -34.31 | -66.92 | -99.42 | -102.1 | -169.3 | -218.1 | -212.9 |
| Net margin | - | -697.26% | -717.79% | -296.05% | -1,938.17% | -2,051.05% | -299.75% |
| EPS 2 | -7.300 | -2.110 | -1.640 | -1.380 | -1.870 | -2.160 | -2.070 |
| Free Cash Flow 1 | - | - | - | -104.9 | -151.9 | -186.2 | -205.3 |
| FCF margin | - | - | - | -304.27% | -1,739.08% | -1,750.78% | -289.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 07/05/21 | 21/03/22 | 09/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.559 | 2.664 | 4.192 | 3.303 | 3.692 | 3.502 | 3.755 | 23.66 | 3.558 | 2.429 | 2 | 2 | 2.033 | 5 | 6 |
| EBITDA 1 | - | - | - | - | - | - | - | - | -36.7 | - | -44.13 | -46.22 | -48.41 | - | - |
| EBIT 1 | -20.4 | -20.85 | -28.43 | -26.54 | -30.58 | -31.12 | -32.87 | -14.63 | -37.44 | -46 | -48.75 | -50.4 | -52.75 | -55 | -62 |
| Operating Margin | -797.38% | -782.77% | -678.22% | -803.42% | -828.22% | -888.52% | -875.31% | -61.84% | -1,052.33% | -1,893.87% | -2,437.5% | -2,520% | -2,594.27% | -1,100% | -1,033.33% |
| Earnings before Tax (EBT) 1 | -18.16 | -19.09 | -26.7 | -26.65 | -26.92 | -28.04 | -29.52 | -10 | -34.31 | -41.23 | -45.57 | -47.61 | -50.16 | -53 | -60 |
| Net income 1 | -18.48 | -19.09 | -26.7 | -26.65 | -26.99 | -28.04 | -29.52 | -10 | -34.5 | -41.23 | -41.43 | -42.57 | -44.3 | -53 | -60 |
| Net margin | -722.12% | -716.52% | -636.86% | -806.75% | -731.01% | -800.8% | -786.13% | -42.27% | -969.79% | -1,697.57% | -2,071.67% | -2,128.33% | -2,178.69% | -1,060% | -1,000% |
| EPS 2 | -0.3100 | -0.3200 | -0.4400 | -0.4400 | -0.4400 | -0.4600 | -0.4800 | -0.1200 | -0.3900 | -0.4600 | -0.4525 | -0.4675 | -0.4725 | -0.5200 | -0.6000 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21/03/22 | 09/05/22 | 09/08/22 | 08/11/22 | 09/03/23 | 09/05/23 | 08/08/23 | 07/11/23 | 11/03/24 | 07/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -105 | -152 | -186 | -205 |
| ROE (net income / shareholders' equity) | - | -36.7% | -28.9% | -30.5% | -56.4% | -85.4% | -26.8% |
| ROA (Net income/ Total Assets) | - | - | -24.4% | -25.3% | -54.6% | -216% | -174% |
| Assets 1 | - | - | 408.1 | 403 | 310 | 100.8 | 122.3 |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | -1.030 | -1.500 | -1.260 | -1.130 | -2.150 | -2.590 |
| Capex 1 | - | 2.12 | - | 11.6 | 11.9 | 13 | 13.4 |
| Capex / Sales | - | 22.1% | - | 33.68% | 136.26% | 122.43% | 18.79% |
| Announcement Date | 07/05/21 | 21/03/22 | 09/03/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.5
USD
Average target price
19.75
USD
Spread / Average Target
+464.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.92% | 316M | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- CRBU Stock
- Financials Caribou Biosciences, Inc.